BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 9862728)

  • 1. Peptide modification or blocking of CD8, resulting in weak TCR signaling, can activate CTL for Fas- but not perforin-dependent cytotoxicity or cytokine production.
    Kessler B; Hudrisier D; Schroeter M; Tschopp J; Cerottini JC; Luescher IF
    J Immunol; 1998 Dec; 161(12):6939-46. PubMed ID: 9862728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficiency of antigen recognition by CD8+ CTL clones is determined by the frequency of serial TCR engagement.
    Hudrisier D; Kessler B; Valitutti S; Horvath C; Cerottini JC; Luescher IF
    J Immunol; 1998 Jul; 161(2):553-62. PubMed ID: 9670927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cell receptor-induced Fas ligand expression in cytotoxic T lymphocyte clones is blocked by protein tyrosine kinase inhibitors and cyclosporin A.
    Anel A; Buferne M; Boyer C; Schmitt-Verhulst AM; Golstein P
    Eur J Immunol; 1994 Oct; 24(10):2469-76. PubMed ID: 7523141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of epitope modification on T cell receptor-ligand binding and antigen recognition by seven H-2Kd-restricted cytotoxic T lymphocyte clones specific for a photoreactive peptide derivative.
    Kessler BM; Bassanini P; Cerottini JC; Luescher IF
    J Exp Med; 1997 Feb; 185(4):629-40. PubMed ID: 9034142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CTL activation is induced by cross-linking of TCR/MHC-peptide-CD8/p56lck adducts in rafts.
    Doucey MA; Legler DF; Boucheron N; Cerottini JC; Bron C; Luescher IF
    Eur J Immunol; 2001 May; 31(5):1561-70. PubMed ID: 11465114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
    Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS
    J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRL/lpr CD4- CD8- and CD8+ T cells, respectively, mediate Fas-dependent and perforin cytotoxic pathways.
    Benihoud K; Bonardelle D; Bobé P; Kiger N
    Eur J Immunol; 1997 Feb; 27(2):415-20. PubMed ID: 9045912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing the relative role of perforin/granzyme versus Fas/Fas ligand cytotoxic pathways in CD8+ T cell-mediated insulin-dependent diabetes mellitus.
    Kreuwel HT; Morgan DJ; Krahl T; Ko A; Sarvetnick N; Sherman LA
    J Immunol; 1999 Oct; 163(8):4335-41. PubMed ID: 10510373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity.
    Kataoka T; Shinohara N; Takayama H; Takaku K; Kondo S; Yonehara S; Nagai K
    J Immunol; 1996 May; 156(10):3678-86. PubMed ID: 8621902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Class I- and class II-reactive TCRs coexpressed on CD4+ T cells both trigger CD4/CD8-shared and CD4-unique functions.
    Asnagli H; Schmitt-Verhulst AM; Guimezanes A
    J Immunol; 1997 May; 158(10):4533-42. PubMed ID: 9144464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated alpha beta-CD8+, but not alpha alpha-CD8+, TCR-alpha beta+ murine intestinal intraepithelial lymphocytes can mediate perforin-based cytotoxicity, whereas both subsets are active in Fas-based cytotoxicity.
    Gelfanov V; Gelfanova V; Lai YG; Liao NS
    J Immunol; 1996 Jan; 156(1):35-41. PubMed ID: 8598484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two types of anti-TL (thymus leukemia) CTL clones with distinct target specificities: differences in cytotoxic mechanisms and accessory molecule requirements.
    Tsujimura K; Takahashi T; Iwase S; Matsudaira Y; Kaneko Y; Yagita H; Obata Y
    J Immunol; 1998 Jun; 160(11):5253-61. PubMed ID: 9605121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a population of CD4+ CTL that utilizes a perforin- rather than a Fas ligand-dependent cytotoxic mechanism.
    Williams NS; Engelhard VH
    J Immunol; 1996 Jan; 156(1):153-9. PubMed ID: 8598456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fratricide of CD8+ cytotoxic T lymphocytes is dependent on cellular activation and perforin-mediated killing.
    Su MW; Pyarajan S; Chang JH; Yu CL; Jin YJ; Stierhof YD; Walden P; Burakoff SJ
    Eur J Immunol; 2004 Sep; 34(9):2459-70. PubMed ID: 15307178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human purified protein derivative-specific CD4+ T cells use both CD95-dependent and CD95-independent cytolytic mechanisms.
    Lewinsohn DM; Bement TT; Xu J; Lynch DH; Grabstein KH; Reed SG; Alderson MR
    J Immunol; 1998 Mar; 160(5):2374-9. PubMed ID: 9498779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-2 induces Fas ligand/Fas (CD95L/CD95) cytotoxicity in CD8+ and CD4+ T lymphocyte clones.
    Esser MT; Dinglasan RD; Krishnamurthy B; Gullo CA; Graham MB; Braciale VL
    J Immunol; 1997 Jun; 158(12):5612-8. PubMed ID: 9190908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered peptide ligands trigger perforin- rather than Fas-dependent cell lysis.
    Bachmann MF; Ohteki T; Faienza KM; Zakarian A; Kägi D; Speiser DE; Ohashi PS
    J Immunol; 1997 Nov; 159(9):4165-70. PubMed ID: 9379009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perforin-dependent cytotoxic activity and lymphokine secretion by CD4+ T cells are regulated by CD8+ T cells.
    Williams NS; Engelhard VH
    J Immunol; 1997 Sep; 159(5):2091-9. PubMed ID: 9278294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perforin and Fas induced by IFNgamma and TNFalpha mediate beta cell death by OT-I CTL.
    McKenzie MD; Dudek NL; Mariana L; Chong MM; Trapani JA; Kay TW; Thomas HE
    Int Immunol; 2006 Jun; 18(6):837-46. PubMed ID: 16574667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing.
    Rivoltini L; Radrizzani M; Accornero P; Squarcina P; Chiodoni C; Mazzocchi A; Castelli C; Tarsini P; Viggiano V; Belli F; Colombo MP; Parmiani G
    J Immunol; 1998 Aug; 161(3):1220-30. PubMed ID: 9686582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.